Sonnet BioTherapeutics (SONN) shares were up 3% Friday after the company said that safety results from a phase 1b/2a trial of SON-1010 plus atezolizumab in patients with advanced solid tumors or platinum-resistant ovarian cancer were "positive."
The study aimed to test the safety, tolerability, and effectiveness of increasing doses of SON-1010 with atezolizumab. The main goal was to find the maximum tolerated dose when combined with the immune checkpoint inhibitor. A total of 19 patients were treated, and one patient with platinum-resistant ovarian cancer showed a partial response at the highest dose, the company said.
Based on positive feedback from the Safety Review Committee, the biotechnology company also said that the study will move to an expansion phase, which will assess the preliminary effects of the combination at the highest dose, leading to a phase 2a comparison with the standard treatment.
Price: 1.31, Change: +0.04, Percent Change: +3.07
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。